This study is looking at whether metformin hydrochloride can improve how ion channels (tiny tunnels that let charged particles in and out of cells) work in the airways of people with cystic fibrosis (CF) who also have cystic fibrosis-related diabetes (CFRD). You might be able to join if you are over 18, have CF, and have been taking certain CFTR modulator therapies (like ivacaftor or elexacaftor/tezacaftor/ivacaftor) for at least 30 days. You also need to have CFRD and still have high blood sugar even after starting your modulator therapy. The study will look at changes in a specific ion channel (BK channel) gene expression over 14 weeks of metformin treatment. The current status of this study is unclear.

Study design

This is an interventional study planning to enroll up to 30 participants. It involves a dose-escalation of metformin hydrochloride.

What's involved

You would start with a lower dose of metformin hydrochloride, increasing it over two weeks, and then continue at 1000 mg twice daily for 14 weeks. You would also take a daily vitamin B12 supplement for the duration of the trial.

Compensation

Not stated in the trial record.

Follow-up

The primary endpoint is measured through week 14 of metformin treatment.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.